OncoGenex in top 10 most innovative companies

OncoGenex Pharmaceuticals (NASDAQ:OGXI) has been named as one of the top ten companies in the biotech industry in the March 2011 issue of Fast Company, as part of the magazine’s annual list of the “Most Innovative Companies”. “We are honored to be ranked as a top biotech by a magazine that recognizes creative thinking and intelligent [...]

Teva and OncoGenex start second Phase 3 trial

Teva Pharmaceuticals (NASDAQ: TEVA) and OncoGenex Pharmaceuticals (NASDAQ: OGXI) initiated their second pivotal trial evaluating their custirsen drug as a first line therapy for the treatment of castrate-resistant prostate cancer (CRPC). The Synergy trial will be conducted in some 125 cancer centres with designated recruitment of 800 men with metastatic CRPC, who have disease progression [...]

OncoGenex starts prostate cancer trial

OncoGenex Pharmaceuticals (NASDAQ:OGXI) has initiated a randomized, investigator-sponsored Phase 2 trial of its OGX-427 drug candidate in men with metastatic prostate cancer. The study will enrol up to 72 men who have minimally symptomatic or asymptomatic advanced prostate cancer and who have not yet received chemotherapy. It is designed to determine the potential benefit of [...]

OncoGenex results in peer-reviewed journal

Phase 2 results of OncoGenex Pharmaceuticals’ (NASDAQ:OGXI) curtirsen drug, showing a survival benefit in patients with advanced prostate cancer, have been published in the Journal of Clinical Oncology. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone chemotherapy was 23.8 months, compared with 16.9 months for patients treated with docetaxel/prednisone [...]

Canadians’ data heading to ASCO

Versant Partners analyst Doug Loe has compiled a list of six biotech companies that will have data presented at the American Society of Clinical Oncology meeting on June 4 to 8.  He expects: · AEterna Zentaris (NASDAQ:AEZS; TSX:AEZ) to report final data from its 43-patient Phase 2 advanced ovarian cancer trial with its AEZS-108 drug, [...]